We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

556 hedge funds and large institutions have $15.6B invested in BioMarin Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 103 funds opening new positions, 187 increasing their positions, 176 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more first-time investments, than exits

New positions opened: 103 | Existing positions closed: 47

60% more funds holding in top 10

Funds holding in top 10: 5 → 8 (+3)

15% more capital invested

Capital invested by funds: $13.6B → $15.6B (+$2.02B)

14% more call options, than puts

Call options by funds: $157M | Put options by funds: $137M

9% more funds holding

Funds holding: 511 → 556 (+45)

6% more repeat investments, than reductions

Existing positions increased: 187 | Existing positions reduced: 176

0.29% more ownership

Funds ownership: 96.25% → 96.54% (+0.29%)

Holders
556
Holders Change
+45
Holders Change %
+8.81%
% of All Funds
8.56%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.12%
New
103
Increased
187
Reduced
176
Closed
47
Calls
$157M
Puts
$137M
Net Calls
+$19.8M
Net Calls Change
+$85.5M

Top Buyers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
+$237M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$121M
3
Citadel Advisors
Citadel Advisors
Florida
+$108M
4
PA
Perceptive Advisors
New York
+$97.4M
5
ACA
Avoro Capital Advisors
New York
+$76.3M

Top Sellers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
-$410M
2
JP Morgan Chase
JP Morgan Chase
New York
-$135M
3
BlackRock
BlackRock
New York
-$117M
4
Goldman Sachs
Goldman Sachs
New York
-$55.4M
5
DLPIC
Davide Leone & Partners Investment Company
United Kingdom
-$55.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
FWIA
26
Fort Washington Investment Advisors
Ohio
$101M +$45.5M +551,729 +93%
Rockefeller Capital Management
27
Rockefeller Capital Management
New York
$101M -$992K -12,022 -1%
UBS AM
28
UBS AM
Illinois
$100M +$3.73M +45,170 +4%
First Trust Advisors
29
First Trust Advisors
Illinois
$99.4M +$3.46M +41,888 +4%
Charles Schwab
30
Charles Schwab
California
$97.3M +$4.09M +49,535 +5%
Legal & General Group
31
Legal & General Group
United Kingdom
$95.9M -$1.31M -15,908 -1%
CCM
32
Camber Capital Management
Massachusetts
$89.7M -$11.1M -135,000 -12%
Deutsche Bank
33
Deutsche Bank
Germany
$83.1M +$3.98M +48,216 +5%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$81.4M +$12.1M +146,110 +19%
N
35
Natixis
France
$78.2M -$33.6M -407,019 -32%
O
36
OrbiMed
New York
$76.1M +$61.9M +749,980 +676%
Point72 Asset Management
37
Point72 Asset Management
Connecticut
$72.6M +$2.48M +30,007 +4%
Goldman Sachs
38
Goldman Sachs
New York
$72M -$55.4M -671,512 -45%
N
39
Nuveen
North Carolina
$70.5M -$1.27M -15,422 -2%
Victory Capital Management
40
Victory Capital Management
Texas
$65.1M +$6.85K +83 +0%
Millennium Management
41
Millennium Management
New York
$62.6M -$11.6M -140,452 -17%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$62.1M -$167K -2,022 -0.3%
Swiss National Bank
43
Swiss National Bank
Switzerland
$61.6M -$2.12M -25,700 -4%
Renaissance Technologies
44
Renaissance Technologies
New York
$57.5M +$22.2M +269,589 +71%
Marshall Wace
45
Marshall Wace
United Kingdom
$55.6M +$24.2M +293,449 +87%
EAM
46
Erste Asset Management
Austria
$54.2M – – –
Sumitomo Mitsui Trust Group
47
Sumitomo Mitsui Trust Group
Japan
$49.8M +$2.83M +34,324 +6%
Jennison Associates
48
Jennison Associates
New York
$48.8M +$45.6M +552,544 New
Dimensional Fund Advisors
49
Dimensional Fund Advisors
Texas
$48.8M +$2.21M +26,813 +5%
SI
50
Scout Investments
Missouri
$47.3M +$9.52M +115,432 +27%
1
2
3 4 5

BMRN Hedge Fund Activity: Q4 2021 in Review

556 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2021, worth a combined $15.6B — up 15% from $13.6B a quarter earlier.

Buyers outnumbered sellers: 103 funds opened new BMRN positions and 47 closed out — a net gain of 56 holders — while 187 added to existing stakes and 176 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $237M. The largest seller was Capital Research Global Investors, cutting an estimated $410M.

  • 556 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2021, up from 511 in Q3 2021.
  • Funds reported $15.6B of BioMarin Pharmaceuticals stock for Q4 2021, up 15% quarter-over-quarter.
  • 103 funds opened new BioMarin Pharmaceuticals positions in Q4 2021 and 47 closed out, a net change of +56 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2021 was Viking Global Investors, an estimated $237M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2021 was Capital Research Global Investors, an estimated $410M sold.

Based on aggregated 13F filings for Q4 2021.